Xie, Jianling, Shen, Kaikai ORCID: https://orcid.org/0000-0002-3891-7231, Jones, Ashley T., Yang, Jian ORCID: https://orcid.org/0000-0003-2631-4553, Tee, Andrew R. ORCID: https://orcid.org/0000-0002-5577-4631, Shen, Ming Hong ORCID: https://orcid.org/0000-0002-3891-7231, Yu, Mengyuan, Irani, Swati, Wong, Derick, Merrett, James E., Lenchine, Roman V., De Poi, Stuart, Jensen, Kirk B., Trim, Paul J., Snel, Marten F., Kamei, Makoto, Martin, Sally Kim, Fitter, Stephen, Tian, Shuye, Wang, Xuemin, Butler, Lisa M., Zannettino, Andrew C. W. and Proud, Christopher G. 2021. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. Cellular and Molecular Life Sciences 78 (1) , 249–270. 10.1007/s00018-020-03491-1 |
Jones, Ashley T., Yang, Jian ORCID: https://orcid.org/0000-0003-2631-4553, Narov, Kalin, Henske, Elizabeth P, Sampson, Julian R. ORCID: https://orcid.org/0000-0002-2902-2348 and Shen, Ming Hong ORCID: https://orcid.org/0000-0002-3891-7231 2019. Allosteric and ATP-competitive inhibitors of mTOR effectively suppress tumor progression-associated epithelial-mesenchymal transition in the kidneys of Tsc2+/− Mice. Neoplasia 21 (8) , pp. 731-739. 10.1016/j.neo.2019.05.003 |
Jones, Ashley T., Narov, Kalin, Yang, Jian ORCID: https://orcid.org/0000-0003-2631-4553, Sampson, Julian R. ORCID: https://orcid.org/0000-0002-2902-2348 and Shen, Ming Hong ORCID: https://orcid.org/0000-0002-3891-7231 2019. Efficacy of dual inhibition of glycolysis and glutaminolysis for therapy of renal lesions in Tsc2+/− Mice1. NEOPLASIA 21 (2) , pp. 230-238. 10.1016/j.neo.2018.12.003 |
Jones, Ashley Thomas
2019.
Targeting MTOR and metabolic pathways for anti-tumour therapy in a TSC2+/- mouse model.
PhD Thesis,
Cardiff University.
Item availability restricted. |
Johnson, Charlotte E. ORCID: https://orcid.org/0000-0003-1954-5142, Dunlop, Elaine A. ORCID: https://orcid.org/0000-0002-9209-7561, Seifan, Sara, McCann, Henry D., Hay, Trevor, Parfitt, Geraint J. ORCID: https://orcid.org/0000-0002-8704-7906, Jones, Ashley T., Giles, Peter J. ORCID: https://orcid.org/0000-0003-3143-6854, Shen, Ming H. ORCID: https://orcid.org/0000-0002-3891-7231, Sampson, Julian R. ORCID: https://orcid.org/0000-0002-2902-2348, Errington, Rachel J. ORCID: https://orcid.org/0000-0002-8016-4376, Davies, D. Mark and Tee, Andrew R. ORCID: https://orcid.org/0000-0002-5577-4631 2018. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir−bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. Oncogene 37 , pp. 5913-5925. 10.1038/s41388-018-0381-2 |
Narov, Kalin, Yang, Jian ORCID: https://orcid.org/0000-0003-2631-4553, Samsel, Paulina, Jones, Ashley, Sampson, Julian R ORCID: https://orcid.org/0000-0002-2902-2348 and Shen, Ming Hong ORCID: https://orcid.org/0000-0002-3891-7231 2017. The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+/- mice through suppression of cell proliferation and induction of apoptosis. Oncotarget , 17215. 10.18632/oncotarget.17215 |
Yang, Jian ORCID: https://orcid.org/0000-0003-2631-4553, Samsel, Paulina A., Narov, Kalin, Jones, Ashley, Gallacher, Daniel, Gallacher, John, Sampson, Julian Roy ORCID: https://orcid.org/0000-0002-2902-2348 and Shen, Ming Hong ORCID: https://orcid.org/0000-0002-3891-7231 2017. Combination of everolimus with sorafenib for solid renal tumours in Tsc2+/- mice is superior to everolimus alone. Neoplasia 19 (2) , pp. 112-120. 10.1016/j.neo.2016.12.008 |
Harvey, Ann K, Lelos, Mariah Jillian ORCID: https://orcid.org/0000-0001-7102-055X, Greenhill, Claire J., Jones, Ashley, Clinch, Susanne, Newton, Michael, Dunnett, Stephen Bruce ORCID: https://orcid.org/0000-0003-1826-1578, Wyatt, Sean Lee ORCID: https://orcid.org/0000-0002-0572-234X, Williams, Anwen Sian ORCID: https://orcid.org/0000-0001-6118-020X and Jones, Simon Arnett ORCID: https://orcid.org/0000-0001-7297-9711 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2 (2) , 033. 10.23937/2469-5726/1510033 |